{"url_path":"/sec/crbp/8-k/2026-05-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1595097/0001193125-26-222890-index.html","accession_number":"0001193125-26-222890","cik":"0001595097","ticker":"CRBP","issuer_name":"Corbus Pharmaceuticals Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1595097/0001193125-26-222890-index.html","primary_entity_key":"0001595097","primary_entity_name":"Corbus Pharmaceuticals Holdings, Inc."},"word_count":98,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits:\n\nExhibit No.\n\nDescription\n\n10.1\n\n[Amendment to the Corbus Pharmaceuticals Holdings, Inc. 2024 Equity Compensation Plan.](crbp-ex10_1.htm)\n\n99.1\n\n \n\n[Press Release issued by Corbus Pharmaceuticals Holdings, Inc. dated May 14, 2026.](crbp-ex99_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nCorbus Pharmaceuticals Holdings, Inc.\n\nDate:\n\nMay 14, 2026\n\nBy:\n\n/s/ Yuval Cohen\n\nName: Yuval Cohen\nTitle: Chief Executive Officer"}